Alzheimer's Disease Trials in Georgia

A listing of Alzheimer's Disease Trials in Georgia actively recruiting patient volunteers.

Search by Name
Filter by Condition
Alzheimer's Disease
33 trials found

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease


The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and w ...

Conditions: Mild Cognitive Impairment, Alzheimer Disease

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease


This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.

Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Phase: Phase 2/3

Faith-Based Toolbox for African Americans With Dementia


The purpose of this study is to create and test faith-based activities that might be useful for African American adults with moderate and severe dementia and their caregivers. A total of 60 people will take part in the intervention; 30 people with moderate and severe dementia and 30 family caregivers.

Conditions: Alzheimer Disease, Dementia
Phase: Not Applicable

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease


The purpose of this study is to investigate the safety of a single dose of Lu AF87908, how well it is tolerated and what the body does to the drug in healthy participants and participants with Alzheimer's disease.

Conditions: Healthy, Alzheimer Disease

TRC-PAD Program: In-Clinic Trial-Ready Cohort


The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud ...

Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD


This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, the ...

Conditions: Alzheimer Disease

Longitudinal Early-onset Alzheimer's Disease Study Protocol


The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol


Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas ...

Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001


The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Phase: Phase 2/3

Browse by Alzheimer's Disease by City